Pharmacyclics wins 2nd FDA approval for blood cancer drug Imbruvica

Pharmacyclics Inc. won its second Food and Drug Administration approval Wednesday for the cancer-fighting drug Imbruvica, netting the Sunnyvale company a $60 million milestone payment from a unit of Johnson & Johnson...